MCID: SPN186
MIFTS: 65

Spinal Cord Injury

Categories: Bone diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Spinal Cord Injury

MalaCards integrated aliases for Spinal Cord Injury:

Name: Spinal Cord Injury 38 76 54 59
Spinal Cord Injuries 43

Characteristics:

Orphanet epidemiological data:

59
spinal cord injury
Prevalence: 1-5/10000 (Europe);

Classifications:



External Ids:

Orphanet 59 ORPHA90058
ICD10 via Orphanet 34 T09.3
UMLS via Orphanet 74 C0037929

Summaries for Spinal Cord Injury

MedlinePlus : 43 Your spinal cord is a bundle of nerves that runs down the middle of your back. It carries signals back and forth between your body and your brain. A spinal cord injury disrupts the signals. Spinal cord injuries usually begin with a blow that fractures or dislocates your vertebrae, the bone disks that make up your spine. Most injuries don't cut through your spinal cord. Instead, they cause damage when pieces of vertebrae tear into cord tissue or press down on the nerve parts that carry signals. Spinal cord injuries can be complete or incomplete. With a complete spinal cord injury, the cord can't send signals below the level of the injury. As a result, you are paralyzed below the injury. With an incomplete injury, you have some movement and sensation below the injury. A spinal cord injury is a medical emergency. Immediate treatment can reduce long-term effects. Treatments may include medicines, braces or traction to stabilize the spine, and surgery. Later treatment usually includes medicines and rehabilitation therapy. Mobility aids and assistive devices may help you to get around and do some daily tasks. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Spinal Cord Injury, also known as spinal cord injuries, is related to brain injury and traumatic brain injury. An important gene associated with Spinal Cord Injury is RTN4IP1 (Reticulon 4 Interacting Protein 1), and among its related pathways/superpathways are Innate Immune System and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Pregabalin and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include Bone and Adipose, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

NINDS : 54 A spinal cord injury usually begins with a sudden, traumatic blow to the spine that fractures or dislocates vertebrae. The damage begins at the moment of injury when displaced bone fragments, disc material, or ligaments bruise or tear into spinal cord tissue. Most injuries to the spinal cord don't completely sever it. Instead, an injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy axons -- extensions of nerve cells that carry signals up and down the spinal cord between the brain and the rest of the body. An injury to the spinal cord can damage a few, many, or almost all of these axons. Some injuries will allow almost complete recovery. Others will result in complete paralysis

Wikipedia : 76 A spinal cord injury (SCI) is damage to the spinal cord that causes temporary or permanent changes in... more...

Related Diseases for Spinal Cord Injury

Diseases related to Spinal Cord Injury via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 379)
# Related Disease Score Top Affiliating Genes
1 brain injury 30.9 BDNF CASP3 GFAP IL6
2 traumatic brain injury 30.7 AQP4 BDNF CASP3 GFAP IL6
3 ischemia 30.4 CASP3 GFAP NOS1 NOS2
4 myelitis 30.1 AQP4 IL6 TNF
5 prostatitis 30.1 IL6 TGFB1 TNF
6 arteries, anomalies of 30.1 IL6 MMP9 TNF
7 spinal cord disease 30.0 AQP4 GDNF IL6 TNF
8 end stage renal failure 29.9 IL6 TGFB1 TNF
9 multiple sclerosis 29.9 AQP4 BDNF GFAP IL6 MMP9 NOS2
10 transverse myelitis 29.8 AQP4 IL6 MMP9 TNF
11 peripheral nervous system disease 29.6 AQP4 IL6 TNF
12 liver disease 29.6 CASP3 IL6 TGFB1 TNF
13 vascular disease 29.5 IL6 MAPK1 MMP9 NOS2 TNF
14 respiratory failure 11.6
15 spasticity 11.6
16 central cord syndrome 11.5
17 neurogenic bowel 11.5
18 paraplegia 11.5
19 acute cystitis 11.5
20 syringomyelia 11.4
21 spinal shock 11.4
22 myoclonus 11.4
23 tethered cord syndrome 11.4
24 swallowing disorders 11.4
25 tethered spinal cord syndrome 11.1
26 central cervical cord syndrome 11.1
27 neurogenic bladder 10.7
28 decubitus ulcer 10.7
29 depression 10.6
30 quadriplegia 10.5
31 pain - chronic 10.5
32 detrusor sphincter dyssynergia 10.4
33 impotence 10.4
34 bacteriuria 10.4
35 anxiety 10.3
36 thrombosis 10.3
37 infertility 10.3
38 scorpion envenomation 10.3 IL6 TNF
39 spondyloarthropathy 1 10.3
40 spondylitis 10.3
41 neural tube defects 10.2
42 autoimmune inner ear disease 10.2 MMP9 TNF
43 leukomalacia 10.2 IL6 TNF
44 aging 10.2
45 wallerian degeneration 10.2
46 angioimmunoblastic lymphadenopathy with dysproteinemia 10.2 IL6 TNF
47 eales disease 10.2 IL6 NOS2 TNF
48 osteoporosis 10.2
49 body mass index quantitative trait locus 1 10.2
50 ichthyosis prematurity syndrome 10.2

Graphical network of the top 20 diseases related to Spinal Cord Injury:



Diseases related to Spinal Cord Injury

Symptoms & Phenotypes for Spinal Cord Injury

GenomeRNAi Phenotypes related to Spinal Cord Injury according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CASP3 GDNF NGFR NOS2 TGFB1 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CASP3 GDNF MAPK1 NGFR NOS2 TGFB1

MGI Mouse Phenotypes related to Spinal Cord Injury:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.54 AQP4 BDNF CASP3 GDNF GFAP GRIN1
2 cellular MP:0005384 10.44 BDNF CASP3 GDNF GFAP GRIN1 IL6
3 growth/size/body region MP:0005378 10.44 AQP4 BDNF CASP3 GDNF GFAP GRIN1
4 homeostasis/metabolism MP:0005376 10.44 AQP4 BDNF CASP3 GFAP GRIN1 IL6
5 digestive/alimentary MP:0005381 10.43 AQP4 BDNF CASP3 GDNF GFAP IL6
6 cardiovascular system MP:0005385 10.42 AQP4 CASP3 GDNF GFAP GRIN1 IL6
7 nervous system MP:0003631 10.36 AQP4 BDNF CASP3 GDNF GFAP GRIN1
8 mortality/aging MP:0010768 10.35 AQP4 BDNF CASP3 GDNF GFAP GRIN1
9 hematopoietic system MP:0005397 10.33 AQP4 CASP3 GDNF GRIN1 IL6 MAPK1
10 immune system MP:0005387 10.3 AQP4 CASP3 GDNF GFAP IL6 MAPK1
11 endocrine/exocrine gland MP:0005379 10.27 AQP4 BDNF CASP3 GDNF IL6 MAPK1
12 integument MP:0010771 10.21 BDNF CASP3 IL6 MAPK1 MMP9 NGFR
13 muscle MP:0005369 10.2 CASP3 GDNF GFAP IL6 MAPK1 MMP9
14 adipose tissue MP:0005375 10.16 IL6 NGFR NOS1 NOS2 PDYN TGFB1
15 craniofacial MP:0005382 10.14 BDNF CASP3 MAPK1 NGFR NOS2 TGFB1
16 reproductive system MP:0005389 10.06 BDNF CASP3 GDNF GRIN1 IL6 MAPK1
17 liver/biliary system MP:0005370 10.04 IL6 MAPK1 NGFR NOS1 NOS2 TGFB1
18 hearing/vestibular/ear MP:0005377 10.03 AQP4 BDNF CASP3 GRIN1 MAPK1 NGFR
19 respiratory system MP:0005388 10.03 AQP4 BDNF CASP3 GRIN1 IL6 MAPK1
20 renal/urinary system MP:0005367 10.02 AQP4 CASP3 GDNF IL6 MMP9 NGFR
21 no phenotypic analysis MP:0003012 10.01 AQP4 BDNF CASP3 GRIN1 NOS1 PDYN
22 skeleton MP:0005390 9.85 CASP3 IL6 MAPK1 MMP9 NGFR NOS1
23 vision/eye MP:0005391 9.44 AQP4 BDNF CASP3 GFAP GRIN1 IL6
24 taste/olfaction MP:0005394 9.35 BDNF CASP3 GRIN1 MAPK1 NGFR

Drugs & Therapeutics for Spinal Cord Injury

Drugs for Spinal Cord Injury (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 436)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 148553-50-8 5486971
2 tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
3
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
4
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
5
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Not Applicable 137-58-6 3676
6
Oxybutynin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 5633-20-5 4634
7
Baclofen Approved Phase 4,Phase 2,Not Applicable 1134-47-0 2284
8
Tadalafil Approved, Investigational Phase 4,Phase 3 171596-29-5 110635
9
Amitriptyline Approved Phase 4 50-48-6 2160
10
Perphenazine Approved Phase 4 58-39-9 4748
11
Teriparatide Approved, Investigational Phase 4,Phase 2 52232-67-4 16133850
12 Piracetam Approved, Investigational Phase 4 7491-74-9
13
Norepinephrine Approved Phase 4,Phase 2,Not Applicable 51-41-2 439260
14
Zoledronic acid Approved Phase 4,Phase 3,Phase 2 118072-93-8 68740
15
Neostigmine Approved, Vet_approved Phase 4,Phase 2,Phase 1,Early Phase 1 59-99-4 4456
16
Darifenacin Approved, Investigational Phase 4,Phase 2 133099-04-4 444031
17
Oxcarbazepine Approved Phase 4 28721-07-5 34312
18
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
19
Midodrine Approved Phase 4,Phase 3,Phase 2 133163-28-7, 42794-76-3 4195
20
Triamcinolone Approved, Vet_approved Phase 4,Not Applicable 124-94-7 31307
21
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 93-14-1 3516
22
Dextromethorphan Approved Phase 4,Phase 2 125-71-3 5360696 5362449
23
Droxidopa Approved, Investigational Phase 4,Phase 1 23651-95-8 443940
24
Cycloserine Approved Phase 4 68-41-7 6234 401
25
Denosumab Approved Phase 4 615258-40-7
26
Trazodone Approved, Investigational Phase 4,Phase 2 19794-93-5 5533
27
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
28
Vancomycin Approved Phase 4 1404-90-6 14969 441141
29
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 77-92-9 311
30
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
31
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
32
Serine Approved, Nutraceutical Phase 4,Phase 2,Phase 3 56-45-1 5951
33 Etiracetam Investigational Phase 4 33996-58-6
34
Lactitol Investigational Phase 4 585-86-4 3871
35 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Psychotropic Drugs Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
38 calcium channel blockers Phase 4,Phase 3,Not Applicable
39 Anti-Anxiety Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
40 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Calcium, Dietary Phase 4,Phase 3,Phase 2,Not Applicable
42 Anticonvulsants Phase 4,Phase 3,Phase 2,Not Applicable
43 Tranquilizing Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
44 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
45 Phosphodiesterase 5 Inhibitors Phase 4,Phase 3,Not Applicable
46 Vardenafil Dihydrochloride Phase 4,Phase 3
47 Vasodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 abobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable
49 Botulinum Toxins Phase 4,Phase 3,Phase 2,Not Applicable
50 Neuromuscular Agents Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1120)
# Name Status NCT ID Phase Drugs
1 Exoskeletons for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943669 Phase 4
2 Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
3 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
4 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
5 A Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
6 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
7 Effect of Tadalafil (Cialis) on the Cardiovascular System of Spinal Cord Injury (SCI) Males Completed NCT01067391 Phase 4 tadalafil;placebo
8 Assess Efficacy in Subjects With Traumatic Spinal Cord Injury Completed NCT00667966 Phase 4 Vardenafil (Levitra, BAY 38-9456), 10 mg;Placebo;Vardenafil (Levitra, BAY 38-9456), 20 mg
9 Chronic Pain in Spinal Cord Injury Completed NCT00006428 Phase 4 Amitriptyline
10 Neuropathic Pain Study With Botulinum Toxin A in Spinal Cord Injury Patients Completed NCT01579500 Phase 4 Botulinum toxin type A;normal saline
11 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury. Completed NCT00320281 Phase 4 botulinum toxin A
12 Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI) Completed NCT00826228 Phase 4 teriparatide
13 Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury Completed NCT00252954 Phase 4 Levetiracetam
14 Pressure Ulcer Healing With Microcyn Completed NCT02001558 Phase 4 Microcyn
15 Project to Improve Symptoms and Mood in People With Spinal Cord Injury Completed NCT00592384 Phase 4 venlafaxine XR;placebo
16 A Study Evaluating the Efficacy and Safety of Sildenafil in Men With Traumatic Spinal Cord Injury and Erectile Dysfunction Completed NCT00654082 Phase 4 sildenafil;placebo
17 Treatment of Fecal Incontinence and Constipation in Patients With Spinal Cord Injury Completed NCT00286520 Phase 4
18 Zoledronic Acid Administration in Acute Spinal Cord Injury Completed NCT02042872 Phase 4 Zoledronic acid
19 Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage Completed NCT00745095 Phase 4 Neostigmine
20 Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed NCT00800462 Phase 4 Oxybutynin Cl;Trospium Cl;Darifenacin Hydrogen Bromide (HBr)
21 Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis Completed NCT00629642 Phase 4 Solifenacin Succinate;Solifenacin Succinate;Oxybutynin Hydrochloride;Placebo
22 A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition Completed NCT00224029 Phase 4 Oxybutynin transdermal system
23 Omega-3 Supplementation for Tetraplegics With Poor Cholesterol Levels Completed NCT01896037 Phase 4
24 Symptom Based Treatment of Neuropathic Pain Completed NCT02180880 Phase 4 Pregabalin and Oxcarbazepine
25 Comparative Study of Intermittent Catheters and Occurrence of Urinary Tract Infections Completed NCT00318591 Phase 4
26 Body Temperature in Persons With Tetraplegia When Exposed to Cold Completed NCT01822535 Phase 4 Midodrine hydrochloride
27 Functional Melatonin Replacement for Sleep Disruptions in Individuals With Tetraplegia Completed NCT00507546 Phase 4 Ramelteon;Placebo
28 Evaluation of the Nursing C-Spine (Phase IV) Completed NCT01353352 Phase 4
29 C7-T1 Epidural Steroid Injections Versus Targeted Injection for Treatment of Cervical Radicular Pain Completed NCT02095197 Phase 4 Triamcinolone 80mg
30 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
31 Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD Recruiting NCT02537899 Phase 4 NeuroAiD
32 Bowel Care and Cardiovascular Function After Spinal Cord Injury Recruiting NCT01567605 Phase 4 Lidocaine lubricant
33 Lower Limb Function After Spinal Cord Injury Recruiting NCT02635893 Phase 4 D-Cycloserine;Placebo
34 Enhancing STDP After Spinal Cord Injury Recruiting NCT02701777 Phase 4 Seromycin;Dextromethorphan;Seromycin Placebo;Dextromethorphan Placebo
35 Denosumab Administration After Spinal Cord Injury Recruiting NCT01983475 Phase 4 Denosumab;Placebo (identical Denosumab volume of normal saline)
36 The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury Recruiting NCT03029442 Phase 4 Denosumab (Prolia)
37 Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury Recruiting NCT03602014 Phase 4 Northera
38 Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury Recruiting NCT02922894 Phase 4 Trazodone;Placebo
39 Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction Recruiting NCT03169582 Phase 4 Avanafil;Sildenafil
40 Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among SCI Recruiting NCT03748290 Phase 4 Pregabalin;Placebo Oral Tablet
41 Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia Recruiting NCT02379156 Phase 4 Midodrine Hydrochloride
42 Nerve Transfer Reconstruction in the Tetraplegic Upper Extremity Recruiting NCT01579604 Phase 4
43 Intrathecal (IT) Baclofen Drug Distribution Recruiting NCT02903823 Phase 4 Baclofen bolus injection
44 Prevention of Bladder Dysfunction in Acute Spinal Cord Injury Active, not recruiting NCT01698138 Phase 4 Onabotulinumtoxin A;Placebo
45 Once Weekly GLP-1 in Persons With Spinal Cord Injury Not yet recruiting NCT03292315 Phase 4 Exenatide 2 MG Injection [Bydureon]
46 Treatment of Chemotherapy-related Hiccups With Baclofen Not yet recruiting NCT03778281 Phase 4 Baclofen;Methoxyclopramide
47 Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury Terminated NCT02355938 Phase 4 Fidaxomicin 200 mg;Placebo;Vancomycin
48 Vitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured Terminated NCT00869427 Phase 4 vitamin C
49 Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder Terminated NCT01023269 Phase 4
50 Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury Withdrawn NCT02970773 Phase 4 Rivaroxaban Oral Tablet

Search NIH Clinical Center for Spinal Cord Injury

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Spinal Cord Injury cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Spinal Cord Injury:
Adipose spheroid-derived Schwann cells for the treatment of spinal cord injury
Bone marrow-derived hematopoietic stem cells for spinal cord injury
Cerecellgram-Spine, bone marrow-derived mesenchymal stem cells for treatment of chronic spinal cord injury
GRNOPC1, hESC-derived oligodendrocyte progenitor cells for spinal cord injury
HuCNS-SC�, human central nervous system stem cells for neurological diseases
MultiStem�, bone marrow-derived cells for neurological disorders
NSI-566, spinal cord stem cells for neurological disorders
RNL-Astrostem�, adipose-derived mesenchymal stem cells for treatment of spinal cord injury
Schwann cells for treatment of spinal cord injury
Umbilical cord-derived mesenchymal stem cells for treatment of spinal cord injury
Embryonic/Adult Cultured Cells Related to Spinal Cord Injury:
Schwann-like cells PMIDs: 20083105
Bone marrow-derived hematopoietic stem cells (family) PMIDs: 19364066
Bone marrow-derived mesenchymal stem cells
Oligodendrocyte progenitor-like cells PMIDs: 17996308 17253955
Human neural stem cells (HuCNS-SC�) PMIDs: 16610769
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 23205020 20637752 23020860 21175285 21248119
Fetal spinal cord stem cells (NSI-566) PMIDs: 22415942 19326469
Adipose-derived mesenchymal stem cells PMIDs: 21303266 24341080 22017805
Schwann cells PMIDs: 16629629 23098734 23186720
Schwann cells PMIDs: 16629629 23098734 23186720
Umbilical cord-derived mesenchymal stem cells PMIDs: 23942181

Genetic Tests for Spinal Cord Injury

Anatomical Context for Spinal Cord Injury

MalaCards organs/tissues related to Spinal Cord Injury:

41
Spinal Cord, Bone, Brain, Bone Marrow, Testes, Cortex, Heart
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Spinal Cord Injury:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
4 Peripheral Nervous System Peripheral Nerve Domain Myelinating Schwann Cells Potential therapeutic candidate
5 Spinal Cord Spinal Cord White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
6 Brain Forebrain White Matter Oligodendrocyte Precursor Cells Potential therapeutic candidate
7 Neural Tube dP4 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
8 Neural Tube Anterior Entopeduncular Area Oligodendrocyte Precursor Cells Potential therapeutic candidate
9 Neural Tube Medial Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
10 Neural Tube dP5 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
11 Neural Tube Caudal Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
12 Neural Tube dP3 Neural Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
13 Neural Tube Lateral Ganglionic Eminence Oligodendrocyte Precursor Cells Potential therapeutic candidate
14 Neural Tube Motor Neural Progenitor Domain Oligodendrocyte Precursor Cells Potential therapeutic candidate
15 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Spinal Cord Injury

Articles related to Spinal Cord Injury:

(show top 50) (show all 4830)
# Title Authors Year
1
Investigating neurogenic bowel in experimental spinal cord injury: where to begin? ( 30531001 )
2019
2
Mesenchymal stem cells and the neuronal microenvironment in the area of spinal cord injury. ( 30531002 )
2019
3
Comparison of walking quality variables between incomplete spinal cord injury patients and healthy subjects by using a footscan plantar pressure system. ( 30531020 )
2019
4
Differences in neuroplasticity after spinal cord injury in varying animal models and humans. ( 30531063 )
2019
5
Combinatorial therapies for spinal cord injury: strategies to induce regeneration. ( 30531075 )
2019
6
Role of axon resealing in retrograde neuronal death and regeneration after spinal cord injury. ( 30539805 )
2019
7
Rehabilitation following spinal cord injury: how animal models can help our understanding of exercise-induced neuroplasticity. ( 30539806 )
2019
8
Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis. ( 30539824 )
2019
9
Inhibition of TREM1 reduces inflammation and oxidative stress after spinal cord injury (SCI) associated with HO-1 expressions. ( 30551457 )
2019
10
Development of a motor and somatosensory evoked potentials-guided spinal cord Injury model in non-human primates. ( 30393204 )
2019
11
Relation of selenium status to neuro-regeneration after traumatic spinal cord injury. ( 30466924 )
2019
12
Tanshinone IIA alleviates oxidative damage after spinal cord injury in vitro and in vivo through up-regulating miR-124. ( 30468834 )
2019
13
Comprehensive Care for Persons with Spinal Cord Injury. ( 30470429 )
2019
14
Celastrol inhibits microglial pyroptosis and attenuates inflammatory reaction in acute spinal cord injury rats. ( 30472522 )
2019
15
Distinct roles of angiotensin receptors in autonomic dysreflexia following high-level spinal cord injury in mice. ( 30315807 )
2019
16
Epidural oscillating field stimulation as an effective therapeutic approach in combination therapy for spinal cord injury. ( 30339879 )
2019
17
Spinal cord injury in zebrafish induced by near-infrared femtosecond laser pulses. ( 30389486 )
2019
18
What is the functional relevance of reorganization in primary motor cortex after spinal cord injury? ( 30217521 )
2019
19
Combinatorial lentiviral gene delivery of pro-oligodendrogenic factors for improving myelination of regenerating axons after spinal cord injury. ( 30229864 )
2019
20
Buyang huanwu decoction combined with BMSCs transplantation promotes recovery after spinal cord injury by rescuing axotomized red nucleus neurons. ( 30266421 )
2019
21
Analysis of reactive astrocytes and NG2 proteoglycan in ex vivo rat models of spinal cord injury. ( 30267723 )
2019
22
Engaging pain fibers after a spinal cord injury fosters hemorrhage and expands the area of secondary injury. ( 30268767 )
2019
23
An allogenic therapeutic strategy for canine spinal cord injury using mesenchymal stem cells. ( 30132873 )
2019
24
Pre-operative screening for asymptomatic bacteriuria and associations with post-operative outcomes in patients with spinal cord injury. ( 29578382 )
2018
25
Pifithrin-I1 modulates microglial activation and promotes histological recovery following spinal cord injury. ( 29962076 )
2018
26
Risk factors for dysphagia after a spinal cord injury: a systematic review and meta-analysis. ( 29955090 )
2018
27
Photobiomodulation Optimization for Spinal Cord Injury Rat Phantom Model. ( 29967691 )
2018
28
Trimethylene carbonate-caprolactone conduit with poly-p-dioxanone microfilaments to promote regeneration after spinal cord injury. ( 29174588 )
2018
29
Surgical management of the neurogenic bladder after spinal cord injury. ( 29680953 )
2018
30
'<i>In a blink of an eye your life can change</i>': experiences of players sustaining a rugby-related acute spinal cord injury. ( 29976760 )
2018
31
Relationship of fitness and wheelchair mobility with encounters, avoidances, and perception of environmental barriers among manual wheelchair users with Spinal Cord Injury. ( 29981312 )
2018
32
Positive sexuality in men with spinal cord injury. ( 29967449 )
2018
33
Response to &amp;quot;The neurogenic bowel dysfunction score in patients with spinal cord injury: methodological issues in reliability and validity&amp;quot;. ( 29348689 )
2018
34
Unique sensory and motor behavior in Thy1-GFP-M mice before and after spinal cord injury. ( 29385890 )
2018
35
Medusa's Head: The Complement System in Traumatic Brain and Spinal Cord Injury. ( 28816089 )
2018
36
The Effect of Quetiapine on Treatment of Experimental Acute Spinal Cord Injury. ( 27476924 )
2018
37
The PI3K/Akt/FOXO3a pathway regulates regeneration following spinal cord injury in adult rats through TNF-I+ and p27kip1 expression. ( 29436581 )
2018
38
Comparing disability between traumatic brain injury and spinal cord injury using the 12-item WHODAS 2.0 and the WHO minimal generic data set covering functioning and health. ( 29962230 )
2018
39
The neurogenic bowel dysfunction score in patients with spinal cord injury: methodological issues in reliability and validity. ( 29348690 )
2018
40
FM19G11 and Ependymal Progenitor/Stem Cell Combinatory Treatment Enhances Neuronal Preservation and Oligodendrogenesis after Severe Spinal Cord Injury. ( 29315225 )
2018
41
Treatment patterns of in-patient spasticity medication use after traumatic spinal cord injury: a prospective cohort study. ( 29904191 )
2018
42
Impact of spasticity on transfers and activities of daily living in individuals with spinal cord injury. ( 29334339 )
2018
43
Inhibition of mammalian target of rapamycin complex 1 signaling by n-3 polyunsaturated fatty acids promotes locomotor recovery after spinal cord injury. ( 29436695 )
2018
44
Arm crank ergometry improves cardiovascular disease risk factors and community mobility independent of body composition in high motor complete spinal cord injury. ( 29334345 )
2018
45
Comparison of Single-Session Dose Response Effects of Whole Body Vibration on Spasticity and Walking Speed in Persons with Spinal Cord Injury. ( 29959653 )
2018
46
Quality of life in the subacute period following a cervical traumatic spinal cord injury based on the initial severity of the injury: a prospective cohort study. ( 29970920 )
2018
47
Coping flexibility as predictor of distress in persons with spinal cord injury. ( 29966646 )
2018
48
Baroreflex autonomic control in human spinal cord injury: Physiology, measurement, and potential alterations. ( 28844537 )
2018
49
Diffusion Tensor Imaging in Diagnosis of Post-Traumatic Syringomyelia in Spinal Cord Injury in Rats. ( 29311540 )
2018
50
Obesity cutoff values in Korean men with motor complete spinal cord injury: body mass index and waist circumference. ( 29976960 )
2018

Variations for Spinal Cord Injury

Expression for Spinal Cord Injury

Search GEO for disease gene expression data for Spinal Cord Injury.

Pathways for Spinal Cord Injury

Pathways related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 CASP3 GDNF GRIN1 IL6 MAPK1 MMP9
2
Show member pathways
13.58 BDNF CASP3 GRIN1 IL6 MAPK1 NOS1
3
Show member pathways
13.55 BDNF CASP3 GDNF GRIN1 IL6 MAPK1
4
Show member pathways
13.31 CASP3 GDNF GRIN1 IL6 MAPK1 MMP9
5
Show member pathways
13.29 AQP4 BDNF CASP3 IL6 MAPK1 TGFB1
6
Show member pathways
13.29 BDNF CASP3 IL6 MAPK1 NGFR PLA2G2A
7
Show member pathways
13.09 BDNF IL6 MAPK1 NGFR PLA2G2A TGFB1
8
Show member pathways
13.08 CASP3 IL6 MAPK1 MMP9 TGFB1 TNF
9
Show member pathways
13.06 GRIN1 MAPK1 MMP9 NOS1 NOS2 TGFB1
10
Show member pathways
13.01 BDNF CASP3 IL6 MAPK1 NGFR TNF
11
Show member pathways
12.98 CASP3 IL6 MAPK1 MMP9 NGFR TNF
12
Show member pathways
12.89 CASP3 GDNF IL6 MAPK1 TGFB1 TNF
13 12.84 CASP3 IL6 MAPK1 MMP9 NOS2 TGFB1
14
Show member pathways
12.76 BDNF GRIN1 MAPK1 NGFR PLA2G2A
15 12.76 BDNF CASP3 MAPK1 NGFR TGFB1 TNF
16
Show member pathways
12.72 BDNF IL6 NGFR TGFB1 TNF
17
Show member pathways
12.68 BDNF GRIN1 MAPK1 NOS1 PDYN
18
Show member pathways
12.6 IL6 MAPK1 NOS1 NOS2 TNF
19
Show member pathways
12.51 CASP3 MAPK1 NOS1 PDYN TNF
20
Show member pathways
12.44 IL6 MAPK1 TGFB1 TNF
21
Show member pathways
12.34 CASP3 IL6 MAPK1 MMP9 TNF
22
Show member pathways
12.33 IL6 MAPK1 NOS2 TNF
23 12.31 CASP3 MAPK1 MMP9 TGFB1 TNF
24
Show member pathways
12.28 BDNF IL6 NGFR TGFB1 TNF
25
Show member pathways
12.26 CASP3 MAPK1 NOS2 TGFB1 TNF
26
Show member pathways
12.24 IL6 MAPK1 NOS2 TNF
27
Show member pathways
12.18 MAPK1 PLA2G2A TGFB1 TNF
28 12.13 CASP3 IL6 MAPK1 NOS2 TGFB1 TNF
29
Show member pathways
12.09 BDNF IL6 MAPK1 NGFR TGFB1
30 12.09 BDNF CASP3 GRIN1 MAPK1 NGFR
31 12.01 AQP4 BDNF CASP3 GRIN1 IL6 TNF
32
Show member pathways
12 CASP3 GRIN1 NOS1 TNF
33 11.97 IL6 MMP9 NOS2 TGFB1 TNF
34 11.93 CASP3 IL6 MAPK1 MMP9 TNF
35 11.92 CASP3 IL6 MAPK1 MMP9 NOS2 TGFB1
36 11.89 CASP3 MAPK1 TGFB1
37 11.87 IL6 TGFB1 TNF
38 11.87 CASP3 IL6 MAPK1 TGFB1 TNF
39 11.85 IL6 MAPK1 NOS2
40 11.84 CASP3 IL6 NOS2 TGFB1 TNF
41 11.83 MAPK1 TGFB1 TNF
42 11.8 BDNF GDNF GFAP
43 11.77 IL6 TGFB1 TNF
44 11.71 CASP3 IL6 MMP9
45 11.7 CASP3 MAPK1 MMP9 NOS2
46
Show member pathways
11.7 BDNF CASP3 NGFR RTN4R
47
Show member pathways
11.67 BDNF MAPK1 NGFR
48 11.66 IL6 MMP9 TGFB1 TNF
49 11.66 AQP4 BDNF CASP3 GDNF GFAP GRIN1
50 11.65 CASP3 MMP9 PLA2G2A

GO Terms for Spinal Cord Injury

Cellular components related to Spinal Cord Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.36 BDNF GDNF IL6 KLK8 MAPK1 MMP9
2 membrane raft GO:0045121 9.26 CASP3 NOS1 RTN4R TNF

Biological processes related to Spinal Cord Injury according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 axon guidance GO:0007411 9.88 BDNF GDNF MAPK1 NGFR
2 regulation of signaling receptor activity GO:0010469 9.88 BDNF GDNF IL6 PDYN TGFB1 TNF
3 defense response to Gram-positive bacterium GO:0050830 9.83 IL6 PLA2G2A TNF
4 response to hypoxia GO:0001666 9.83 CASP3 NOS1 NOS2 TGFB1
5 response to organic substance GO:0010033 9.82 CASP3 TGFB1 TNF
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.81 CASP3 NGFR TNF
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.81 IL6 TGFB1 TNF
8 response to lipopolysaccharide GO:0032496 9.81 CASP3 MAPK1 NOS1 NOS2
9 memory GO:0007613 9.8 BDNF GRIN1 KLK8
10 cellular response to organic cyclic compound GO:0071407 9.78 CASP3 TGFB1 TNF
11 response to glucocorticoid GO:0051384 9.77 CASP3 IL6 TNF
12 MAPK cascade GO:0000165 9.77 GDNF GRIN1 MAPK1 TGFB1 TNF
13 negative regulation of neuron projection development GO:0010977 9.76 GFAP NGFR RTN4R
14 learning or memory GO:0007611 9.72 CASP3 GRIN1 MAPK1
15 negative regulation of fat cell differentiation GO:0045599 9.67 IL6 TGFB1 TNF
16 membrane protein intracellular domain proteolysis GO:0031293 9.65 NGFR TGFB1
17 nitric oxide biosynthetic process GO:0006809 9.64 NOS1 NOS2
18 lipopolysaccharide-mediated signaling pathway GO:0031663 9.63 MAPK1 TGFB1 TNF
19 negative regulation of axon regeneration GO:0048681 9.62 KLK8 RTN4R
20 positive regulation of guanylate cyclase activity GO:0031284 9.62 NOS1 NOS2
21 negative regulation of lipid storage GO:0010888 9.61 IL6 TNF
22 Bergmann glial cell differentiation GO:0060020 9.59 GFAP MAPK1
23 arginine catabolic process GO:0006527 9.57 NOS1 NOS2
24 positive regulation of receptor binding GO:1900122 9.56 BDNF MMP9
25 response to wounding GO:0009611 9.56 CASP3 GFAP KLK8 TGFB1
26 positive regulation of neuroinflammatory response GO:0150078 9.54 IL6 TNF
27 neurotrophin TRK receptor signaling pathway GO:0048011 9.5 BDNF CASP3 NGFR
28 peptidyl-cysteine S-nitrosylation GO:0018119 9.48 NOS1 NOS2
29 positive regulation of mononuclear cell migration GO:0071677 9.43 TGFB1 TNF
30 cytokine-mediated signaling pathway GO:0019221 9.43 CASP3 IL6 MMP9 NOS2 TGFB1 TNF
31 positive regulation of glial cell proliferation GO:0060252 9.33 GFAP IL6 TNF
32 positive regulation of apoptotic process GO:0043065 9.17 CASP3 GRIN1 IL6 MMP9 NGFR TGFB1
33 negative regulation of apoptotic process GO:0043066 10.06 CASP3 GDNF IL6 MMP9 NGFR

Molecular functions related to Spinal Cord Injury according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.62 GRIN1 NGFR NOS1 NOS2
2 growth factor activity GO:0008083 9.46 BDNF GDNF IL6 TGFB1
3 arginine binding GO:0034618 9.37 NOS1 NOS2
4 NADPH-hemoprotein reductase activity GO:0003958 9.26 NOS1 NOS2
5 tetrahydrobiopterin binding GO:0034617 8.96 NOS1 NOS2
6 nitric-oxide synthase activity GO:0004517 8.62 NOS1 NOS2

Sources for Spinal Cord Injury

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....